Two cases of statin-induced rhabdomyolysis associated with mononeuropathy.
HMG-CoA reductase inhibitors (statins) are highly effective drugs for prevention of cardiovascular events in high-risk patients. Due to the widespread prescription of these agents, special attention should be given to their rare adverse effects when these may have severe outcomes. Here, we report two cases of localized rhabdomyolysis associated with mononeuropathy in patients taking statins and suggest possible explanations for this uncommon association. Close monitoring for myopathic/neuropathic events is warranted in high-risk patients with pre-existing neuropathies who are taking statins.
Fadini
Gian Paolo
GP
Department of Clinical and Experimental Medicine, University of Padova, Medical School, Padova, Italy. gianpaolofadini@hotmail.com
Manzato
Enzo
E
Crepaldi
Cristina
C
de Kreutzenberg
Saula
S
Tiengo
Antonio
A
Avogaro
Angelo
A
D000328:Adult; D016903:Drug Monitoring; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020422:Mononeuropathies / Q000139:chemically induced* / Q000209:etiology; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000209:etiology; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
Nutr Metab Cardiovasc Dis. 2007 Jan;17(1):32-40
17174224
Drugs Today (Barc). 2005 Apr;41(4):267-93
16034491
Arch Intern Med. 2004 Jul 12;164(13):1427-36
15249352
Atherosclerosis. 2007 Nov;195(1):7-16
17094994
Arch Intern Med. 2006 Jul 24;166(14):1519-24
16864763
Arch Intern Med. 2005 Apr 11;165(7):725-30
15824290
Am J Cardiol. 2006 Apr 17;97(8A):52C-60C
16581329
Am J Med. 2006 May;119(5):400-9
16651050